InvestSMART

Biome Australia Limited (ASX:BIO)

ALERT: Price-sensitive ASX Announcement for BIO
Current share price for BIO : $0.270 -0.135 (-33.33%)+
Announcement
Release
23 Feb 2026 8:44AM
Price at Release
$0.405
Full Release
download
Summary
Biome Australia Limited reported strong financial and business performance for the first half of FY26, with a record net profit of $1.18 million, up 172% compared to the same period last year. The company also achieved record EBITDA of $1.47 million and half-year sales revenue of $12.40 million, marking an increase of 40% from the prior year. Significant business highlights include Biome's recognition as the fastest growing probiotic brand in Australian community pharmacy and a strategic expansion through partnerships in Canada, Ireland, and New Zealand. The company also secured new distribution channels and launched new product innovations. Additionally, Biome commenced a human clinical trial for its proprietary BMB18 strain in collaboration with La Trobe University. Infrastructure enhancements were made with a new warehouse facility in Brunswick, VIC to support growth and international scaling.
Key Points
  • Record H1 net profit of $1.18 million, up 172% from 1H25.
  • Record EBITDA of $1.47 million and sales revenue of $12.40 million.
  • Fastest growing probiotic brand in Australian community pharmacy.
  • Canadian Fullscript distribution partnership secured.
  • BMB18 human clinical trial commenced with La Trobe University.
  • New distribution partnerships with Mecca and Go Vita.
  • New warehouse facility in Brunswick, VIC secured for expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.